《大行報告》花旗上調友邦(01299.HK)目標價至116元 維持「買入」評級
花旗發表研究報告指,雖然受疫情反彈影響,友邦保險(01299.HK)去年第四季新業務價值(NBV)表現較差,將全年NBV跌幅預測由18%進一步下調至31%,但考慮到中國內地業務擴張,將2022年NBV增長率從19%上調至26%。
該行又將第二階段及終端年化新保費(ANP)增長分別上調至10%及3.75%,預料在潛在的積極資本控制措施下,將刺激跨境保險產品銷售。
花旗表示,持續看好友邦保險,特別關注其在內地的長期結構性增長機會,估計通關後來港內地人士業務可能強勁反彈,此外內地放寬資本管制,以及大灣區金融市場互聯互通將為友邦帶來新分銷渠道。花旗將目標價由84元上調至116元,予「買入」評級,並微調2020至2022年每股盈測。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.